THE Co-Occurrence of Jak2 Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated With Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.: Dual Myeloid Disorder Treated With Two Drug Association. Mediterr J Hematol Infect Dis 2025, 17 (1), e2025023. https://doi.org/10.4084/MJHID.2025.023.